We value your privacy
We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
No cookies to display.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
No cookies to display.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
No cookies to display.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
No cookies to display.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
No cookies to display.
EPIDEMIOLOGY OF ANTIBIOTIC USE AND DRIVERS OF CROSS-BORDER PROCUREMENT IN A MEXICAN AMERICAN BORDER COMMUNITY
Antibiotics are one of the most common reported drivers of cross-border healthcare access and a medication of particular concern since indiscriminate or inappropriate use is associated with antimicrobial resistance. Data used in this study were collected during the baseline examination of an ongoing longitudinal cohort study in Starr Country, Texas, one of 14 counties on the Texas-Mexico border. Over 10% of the study cohort reported using antibiotics in the past 30 days with over 60% of all rounds used in the past 12 months sourced from Mexico.
Full Access: Pubmed
ORAL TEBIPENEM PIVOXIL HYDROBROMIDE IN COMPLICATED URINARY TRACT INFECTION
There is a need for oral antibiotic agents that are effective against multidrug-resistant gram-negative uropathogens. In this phase 3, international, double-blind, double-dummy trial, we evaluated the efficacy and safety of orally administered tebipenem pivoxil hydrobromide as compared with intravenous ertapenem in patients with complicated urinary tract infection or acute pyelonephritis. Oral tebipenem pivoxil hydrobromide was noninferior to intravenous ertapenem in the treatment of complicated urinary tract infection and acute pyelonephritis and had a similar safety profile.
Full Access: NEJM
AN IMPORTANT CAUSE OF WIDE COMPLEX TACHYCARDIA
Rapid and accurate distinction between artifact and ventricular tachycardia (VT) is crucial. Misinterpretation of an artifact as VT can lead to unnecessary medical interventions, including initiation of antiarrhythmic drugs, diagnostic coronary angiograms, and even implantation of implantable cardiac defibrillators. Features that help differentiate artifact from true VT include body movement during the wide complex tachycardia, absence of hemodynamic impairment, presence of normal beats in any ECG lead, and unstable ECG baseline before or after.4 Most importantly, if sharp spikes consistent with QRS complexes can be marched through the wide complex tachycardia, as in this case, the diagnosis is almost certainly artifact.
Full Access: JAMA
CHEST CT OF LUNG INJURY 1 YEAR AFTER COVID-19 PNEUMONIA: THE COVILD STUDY
This was a secondary analysis of a prospective, multicenter observational cohort study conducted from April 29 to August 12, 2020 to assess pulmonary abnormalities on chest CT at approximately 2, 3, 6 months, and 1 year after onset of COVID-19 symptoms.
Out of 142 enrolled participants, 91 participants had a 1-year follow-up CT 49/91 (54%) participants, CT abnormalities were observed: 31/91 (34%) participants showed subtle subpleural reticulation, ground-glass opacities or both and 18/91 (20%) participants revealed extensive ground-glass opacities, reticulations, bronchial dilation and/or microcystic changes. Long-term CT abnormalities were common 1 year after COVID-19 pneumonia.
Full Access: RSNA
Notifications